NCT00362687View on ClinicalTrials.gov

GMB: Study of Truvada (TDF+FTC) or Emtricitabine (FTC) Alone Versus HAART Interruption in HIV-Infected Patients With Resistance

PHASE4CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

October 31, 2008

Conditions

HIV Infections

Interventions

DRUG

Truvada (TDF+FTC) alone

tenofovir DF 300 mg and emtricitabine 200 mg in a fixed dose tablet formulation

DRUG

FTC alone

emtricitabine 200 mg

PROCEDURE

No HAART

No HAART

Trial Locations (1)

E-28036

Gilead Sciences, S.L., Madrid

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY